Patents by Inventor María Luz Ortiz Melguizo

María Luz Ortiz Melguizo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compound that can inhibit UBC13-UEV interactions, pharmaceutical compositions and therapeutic uses
    Patent number: 8785430
    Abstract: The invention relates to a compound (I) wherein R is a heterocyclyl radical; R1 and R2 are independently H or alkyl; R3 is H, alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl; R4 and R5 are independently H or alkyl; q is a number selected from 0 and 1; and the salts, solvates, prodrugs or stereoisomers thereof having inhibitory activity for UBC13-UEV interactions and which can be used in the production of pharmaceutical compositions intended for antitumor therapy or the treatment and/or prophylaxis of diseases associated to metabolic pathways involving the UBC13 enzyme, metabolic pathways involving transcriptional factor NF-?B, or pathways involving PCNA or RAD6.
    Type: Grant
    Filed: July 23, 2012
    Date of Patent: July 22, 2014
    Assignee: Consejo Superior de Investigaciones Cientificas
    Inventors: Timothy Thomson Okatsu, Johanna Scheper Sigmund, Ángel Messeguer Peypooh, Gloria Sanclimens Pérez de Rozas, Isabel Masip Masip, Alejandra Moure Fernández, Domingo González Ruiz, Antonio Morreale de León, Maria Luz Ortiz Melguizo, Ma Carmen Fabrega Claveria
  • COMPOUND THAT CAN INHIBIT UBC13-UEV INTERACTIONS, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC USES
    Publication number: 20130237529
    Abstract: The invention relates to a compound (I) wherein R is a heterocyclyl radical; R1 and R2 are independently H or alkyl; R3 is H, alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl; R4 and R5 are independently H or alkyl; q is a number selected from 0 and 1; and the salts, solvates, prodrugs or stereoisomers thereof having inhibitory activity for UBC13-UEV interactions and which can be used in the production of pharmaceutical compositions intended for antitumor therapy or the treatment and/or prophylaxis of diseases associated to metabolic pathways involving the UBC13 enzyme, metabolic pathways involving transcriptional factor NF-?B, or pathways involving PCNA or RAD6.
    Type: Application
    Filed: July 23, 2012
    Publication date: September 12, 2013
    Inventors: María Luz Ortiz Melguizo, Mª Carmen Fabrega Claveria
  • Compound that can inhibit UBC13-UEV interactions, pharmaceutical compositions and therapeutic uses
    Patent number: 8252786
    Abstract: The invention relates to a compound (I) wherein R is a heterocyclyl radical; R1 and R2 are independently H or alkyl; R3 is H, alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl; R4 and R5 are independently H or alkyl; q is a number selected from 0 and 1; and the salts, solvates, prodrugs or stereoisomers thereof having inhibitory activity for UBC13-UEV interactions and which can be used in the production of pharmaceutical compositions intended for antitumor therapy or the treatment and/or prophylaxis of diseases associated to metabolic pathways involving the UBC13 enzyme, metabolic pathways involving transcriptional factor NF-?B, or pathways involving PCNA or RAD6.
    Type: Grant
    Filed: March 7, 2007
    Date of Patent: August 28, 2012
    Assignee: Consejo Superior de Investigaciones Cientificas
    Inventors: Timothy Thomson Okatsu, Johanna Scheper Sigmund, Ángel Messeguer Peypoch, Ángel Ramírez Ortiz, María Luz Ortiz Melguizo, legal representative, Ma Carmen Fabrega Claveria, legal representative, Gloria Sanclimens Pérez de Rozas, Isabel Masip Masip, Alejandra Moure Fernández, Domingo González Ruiz, Antonio Morreale de León
  • COMPOUND THAT CAN INHIBIT UBC13-UEV INTERACTIONS, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC USES
    Publication number: 20110160189
    Abstract: The invention relates to a compound (I) wherein R is a heterocyclyl radical; R1 and R2 are independently H or alkyl; R3 is H, alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl; R4 and R5 are independently H or alkyl; q is a number selected from 0 and 1; and the salts, solvates, prodrugs or stereoisomers thereof having inhibitory activity for UBC13-UEV interactions and which can be used in the production of pharmaceutical compositions intended for antitumor therapy or the treatment and/or prophylaxis of diseases associated to metabolic pathways involving the UBC13 enzyme, metabolic pathways involving transcriptional factor NF-?B, or pathways involving PCNA or RAD6.
    Type: Application
    Filed: March 7, 2007
    Publication date: June 30, 2011
    Inventors: Timothy Thomson Okatsu, Johanna Scheper Sigmund, Angel Messeguer Peypoch, Ángel Ramírez Ortiz, María Luz Ortiz Melguizo, Ma Carmen Fabrega Claveria, Gloria Sanclimens Pérez de Rozas, Isabel Masip Masip, Alejandra Moure Fernández, Domingo González Ruiz, Antonio Morreale de León